Trump administration shakes up pharma industry with 'Buy American' plan

Reining in the high cost of prescription drugs has been a major aim of the Trump administration, marked most notably by the president's 2018 "Blueprint…

By Emily Payne | August 07, 2020 at 11:37 AM

Drug prices Drug manufacturers and other trade industry experts have warned that the new proposal could actually raise drug prices. (Photo: Shutterstock)

Reining in the high cost of prescription drugs has been a major aim of the Trump administration, marked most notably by the president's 2018 "Blueprint to Lower Drug Prices" directive. Since then, the administration has rolled out numerous orders and regulations aimed at bringing reform to the pharmaceutical industry–only to be met with resistance at nearly every turn.

Though many of those initiatives have been slow to get started or stalled by legal challenges, a new executive order from President Trump requiring the government to buy certain drugs from American factories could have some teeth. As reported by Stat News, as much as 90% of the country's supply of generic drugs is manufactured abroad.

Recommended For You

The order, signed Thursday, instructs the FDA to implement the new directive but allows certain drugs to be exempted if making them on U.S. soil proves cost-prohibitive. In addition, the order directs HHS to speed up FDA approval for U.S. drugs and prioritizes government contracts with domestic drug manufacturers.

Drug manufacturers and other trade industry experts have warned that the new proposal could actually raise drug prices, though White House trade advisor Peter Navarro was quick to point out the benefits of having more control over the drug supply chain.

"If we learned anything from the [coronavirus] pandemic, it is simply that we are dangerously overdependent on foreign nations for our essential medicines, for medical supplies — like masks, gloves, goggles and the like — and medical equipment, like ventilators," he said.

NOT FOR REPRINT

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Emily Payne

Emily Payne is director, content analytics for ALM's Business & Finance Markets and former managing editor for BenefitsPRO. A Wisconsin native, she has spent the past decade writing and editing for various athletic and fitness publications. She holds an English degree and Business certificate from the University of Wisconsin.

By Emily Payne | May 08, 2025

Our Advisor of the Year finalists shared the industry developments they're most excited about.

5 exciting things happening in the benefits industry

By Allison Bell | May 08, 2025

Some patients who face access restrictions may end up not using any medication, the analysts at GoodRx warn.

Commercial health plans cover more drugs without restrictions than Medicare, Medicaid: GoodRx

By Emily Payne | May 08, 2025

At this year’s Broker Expo, Lester Morales demonstrated how to connect data and health care spending -- without your audience’s eyes glazing over.

How to use data to tell a story about health care costs
Employer Trends Across the Benefits Landscape: An HR Pulse Survey link

Report

Sponsored by New Benefits

Rising costs & low engagement challenge employers. This HR Pulse Survey reveals key trends from HR leaders across various industries and looks at the opportunities for brokers to elevate service, address pain points, and demonstrate ROI, especially with non-insured benefits.

Identifying Benefits Blind Spots: 3 Steps to Building a Well-Rounded Benefits Playbook link

Guide

Sponsored by New Benefits

Clients expect strategic advice, not just sales. This guide reveals 3 steps to audit benefits, fill gaps, and present holistic strategies that meet client goals and employee needs--positioning employee benefits brokers as trusted advisors.

Benefit Strategy Savers: A Broker's Guide to Solving 2025 Benefit Challenges link

Guide

Sponsored by ArmadaCare

Discover how employer-paid supplemental health benefits can help close coverage gaps, reduce out-of-pocket costs, and boost retention!